checkAd

    ### NEWS Calypte`s Urine HIV-1 Antibody Test - 500 Beiträge pro Seite

    eröffnet am 19.09.02 13:06:03 von
    neuester Beitrag 19.09.02 17:25:25 von
    Beiträge: 15
    ID: 635.360
    Aufrufe heute: 0
    Gesamt: 491
    Aktive User: 0


     Durchsuchen

    Begriffe und/oder Benutzer

     

    Top-Postings

     Ja Nein
      Avatar
      schrieb am 19.09.02 13:06:03
      Beitrag Nr. 1 ()
      PR NEWSWIRE) Calypte`s Urine HIV-1 Antibody Test Now Approved for Life Insur
      Calypte`s Urine HIV-1 Antibody Test Now Approved for Life Insurance Screening
      In All 50 States

      West Virginia Department of Insurance Amends Rule to Include Urine HIV-1
      Antibody Testing

      ALAMEDA, Calif., Sept. 19 /PRNewswire-FirstCall/ --
      Calypte Biomedical Corporation (OTC Bulletin Board: CALY), the developer and
      marketer of the only two FDA-approved HIV-1 antibody tests that can be used on
      urine samples, announced today that the West Virginia Office of the Insurance
      Commissioner has cleared the way for urine HIV screening among life insurance
      applicants in that state. With this decision, Calypte`s urine HIV-1 screening
      test is now approved for use by the life insurance industry in all 50 states.
      Until now, life and health insurance companies writing policies in West
      Virginia have been unable to test specimens other than blood and oral fluid
      for HIV. The Interpretive Rule amendment made by the commissioner is intended
      to serve as a bridge to the effective date of the Legislative Rule, and allows
      the urine-based screening to begin immediately. The Legislative Rule is
      expected to be effective in the spring or summer of 2003.
      "Life Insurance companies have been very receptive to urine-based testing
      as an effective, convenient and cost-effective alternative to blood testing,"
      said Nancy Katz, President and CEO of Calypte Biomedical. "We now have the
      approval of approximately 150 insurance companies to order our tests,
      including nine of the top 10 life insurance underwriters as ranked by policy
      value. The Calypte urine antibody tests are completely non-invasive, which
      results in a painless and comfortable way for insurance applicants to provide
      a specimen. Also, urine testing is safe for those collecting the specimen who
      otherwise would be at risk of contracting HIV from accidental needlestick
      injuries. We are very pleased that the State of West Virginia has made
      progress developing the necessary procedures that allow our life insurance
      customers to expand their utilization of urine testing."
      "Now that West Virginia has joined every other state in approving urine
      screening tests for HIV-1 antibodies, we believe that it will be even easier
      to get our message out to life insurance and other communities that our
      proprietary urine screening test represents the future direction of HIV-1
      screening," said Anthony Cataldo, Calypte`s Chairman.

      About Calypte Biomedical:
      Calypte Biomedical Corporation headquartered in Alameda, California, is a
      public healthcare company dedicated to the development and commercialization
      of urine-based diagnostic products and services for Human Immunodeficiency
      Virus Type 1 (HIV-1), sexually transmitted diseases and other infectious
      diseases. Calypte`s tests include the screening EIA and supplemental Western
      Blot tests, the only two FDA-approved HIV-1 antibody tests that can be used on
      urine samples. When compared with existing blood-based tests, our
      testing algorithms are non-invasive, easier to use, less expensive and have
      significantly less risk than blood-based testing, and they have 99.7%
      sensitivity in subjects previously identified as HIV-1 infected and 100%
      specificity in subjects at low risk when combined with the urine-based Western
      Blot supplemental test. The company believes that accurate, non-invasive
      urine-based testing methods for HIV and other infectious diseases may make
      important contributions to public health by helping to foster an environment
      in which testing may be done safely, economically, and painlessly. Calypte
      markets its products in countries worldwide through international distributors
      and strategic partners.

      Statements in this press release that are not historical facts are
      forward-looking statements within the meaning of the Securities Act of 1933,
      as amended. Those statements include statements regarding the intent, belief
      or current expectations of the Company and its management. Such statements
      reflect management`s current views, are based on certain assumptions and
      involve risks and uncertainties. Actual results, events, or performance may
      differ materially from the above forward-looking statements due to a number of
      important factors, and will be dependent upon a variety of factors, including,
      but not limited to, our ability to obtain additional financing and access
      funds from our existing financing arrangements that will allow us to continue
      our current and future operations and whether demand for our product and
      testing service in domestic and international markets will continue to expand.
      The Company undertakes no obligation to publicly update these forward-looking
      statements to reflect events or circumstances that occur after the date hereof
      or to reflect any change in the Company`s expectations with regard to these
      forward-looking statements or the occurrence of unanticipated events. Factors
      that may impact the Company`s success are more fully disclosed in the
      Company`s most recent public filings with the U.S. Securities and Exchange
      Commission ("SEC"), including its annual report on Form 10-K for the year
      ended December 31, 2001 and its subsequent filings with the SEC.

      For further information, please contact Joe Bunning of Sitrick and
      Company, +1-310-788-2850, for Calypte Biomedical Corporation.

      SOURCE Calypte Biomedical Corporation
      -0- 09/19/2002
      /CONTACT: Joe Bunning of Sitrick and Company, +1-310-788-2850, for
      Calypte Biomedical Corporation/
      /Web site: http://www.calypte.com /
      (CALY)

      CO: Calypte Biomedical Corporation
      ST: California, West Virginia
      IN: MTC BIO HEA OTC INS
      SU: LEG

      *** end of story ***
      Avatar
      schrieb am 19.09.02 13:28:04
      Beitrag Nr. 2 ()
      Ihr wisst was zu tun ist wenn der Kurs heute weiter absackt!

      morchel
      Avatar
      schrieb am 19.09.02 13:32:37
      Beitrag Nr. 3 ()
      @ morchel

      so? was denn? :)

      zur meldung:

      49+1=welch horrende umsatzsteigerungen das jetzt wohl bringen mag...
      ich tippe mal: spätestens zum WE .071
      Avatar
      schrieb am 19.09.02 13:57:45
      Beitrag Nr. 4 ()
      Hallo Leute!
      Habe mich schon gewundert warum der Kurs in Frankfurt von 8 auf 10 Cent wieder gestiegen ist. Wenn ihr mir den Beitrag oben in kleien Sätzen übersetzt kann ich mich mit freuen.
      Danke!!!!!
      Avatar
      schrieb am 19.09.02 14:03:46
      Beitrag Nr. 5 ()
      #4

      der test wurde nun auch im 50. us-bundesstaat zugelassen.


      gab es für die anderen 49 auch jeweils eine eigene PR? würde mich nicht wundern...

      Trading Spotlight

      Anzeige
      Rallye II. – Neuer Anstoß, News und was die Börsencommunity jetzt nicht verpassen will…mehr zur Aktie »
      Avatar
      schrieb am 19.09.02 14:11:10
      Beitrag Nr. 6 ()
      und was heisst das jetzt?
      Avatar
      schrieb am 19.09.02 14:36:18
      Beitrag Nr. 7 ()
      #6

      außer potentiellem umsatzwachstum von 1 oder 2 prozent? nichts.
      Avatar
      schrieb am 19.09.02 14:41:24
      Beitrag Nr. 8 ()
      09/19/2002 (08:40 ET) The Subway.com Covers CALY - Knobias
      09/19/2002 (08:28 ET) TheSubway.com: TheSUBWAY.com announces Stock Focus List -- Potential market movers! - M2 Communications
      09/19/2002 (08:23 ET) TheSUBWAY.com Posts Investment Opinion: Today`s Market Picks! - Business Wire
      09/19/2002 (07:00 ET) Calypte`s Urine HIV-1 Antibody Test Now Approved for Life Insurance Screening In All 50 States - PR Newswire
      09/18/2002 (08:05 ET) New 424B3 just released for CALY - Edgar


      JS200
      Avatar
      schrieb am 19.09.02 15:56:29
      Beitrag Nr. 9 ()
      naja +20% für "nichts" ist doch ok.
      Avatar
      schrieb am 19.09.02 16:08:07
      Beitrag Nr. 10 ()
      naja, 20% für "was" wären mir da doch lieber.
      Avatar
      schrieb am 19.09.02 16:14:05
      Beitrag Nr. 11 ()
      20% = 20%
      Avatar
      schrieb am 19.09.02 16:35:14
      Beitrag Nr. 12 ()
      nichts=nichts
      Avatar
      schrieb am 19.09.02 17:04:22
      Beitrag Nr. 13 ()
      "nichts" = 26%
      Avatar
      schrieb am 19.09.02 17:08:38
      Beitrag Nr. 14 ()
      Wenn das so weiter geht könen auch nichts=50% werden!!!
      Oder wie seht ihr das?
      Bin auch schon seit über 1 Jahr in Caly investiert, auch noch mit Miesen - bin aber optimistisch Caly wird ein Riesenkracher werden!!! Geduld zahlt sich aus.
      See soon
      Avatar
      schrieb am 19.09.02 17:25:25
      Beitrag Nr. 15 ()
      .... leute, leute, leute ....

      schaut mal auf die volumina in den usa - unglaublich!!! - liegt schon bei über 300000 nach gerade mal eineinhalb stunden handel....bei einem solchen wert sehr sehr ordentlich ...

      ... da geht noch was ...


      Beitrag zu dieser Diskussion schreiben


      Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
      Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie
      hier
      eine neue Diskussion.
      ### NEWS Calypte`s Urine HIV-1 Antibody Test